Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Tazemetostat Is Associated with Lower Risk for Safety Outcomes Versus the PI3-Kinases Idelalisib, Duvelisib and Copanlisib, in Patients with Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 2 Prior Systemic Treatments: A Matching-Adjusted Indirect Comparison of Single-Arm Trials

David Proudman, MSc,MPH, Dave Nellesen, PhD, Deepshekhar Gupta, MS, Deyaa Adib, MD, Jay Yang, PhD, Michael Keith, PhD PharmD, Khalid Mamlouk, PharmD, BCOP

Blood (2020) 136 (Supplement 1): 16.

https://doi.org/10.1182/blood-2020-137772

Published: 2020

Journal Articles

A Systematic Literature Review of the Burden of Central Nervous System Complications for Patients with Sickle Cell Disease

Soyon Lee, Pharm.D., Dave Nellesen, PhD, Sedge Lucas, B.A., Jincy Paulose, MD, Vivien A. Sheehan, MDPhD

Blood (2020) 136 (Supplement 1): 10.

https://doi.org/10.1182/blood-2020-140533

Published: 2020

Journal Articles

A Systematic Literature Review of the Burden of Ischemic Priapism in Patients with Sickle Cell Disease

Dave Nellesen, PhD, Sedge Lucas, BA, Che-Rung Liu, MA., Menaka Bhor, PhD, Jincy Paulose, MD, Arthur Burnett, MD MBA

Blood (2019) 134 (Supplement_1): 3467.

https://doi.org/10.1182/blood-2019-128951

Published: 2019

Journal Articles

A Systematic Literature Review to Assess Long-Term Outcomes Associated with Splenectomy in Patients with Chronic Immune Thrombocytopenia

Dave Nellesen, PhD, Qayyim Said, PhD, Nina Shak, Cody Patton, B.S., Sedge Lucas, J. Anthony Graves, MD, PhD, Brigette Nezami, PharmD, Adam Cuker, MD MS

Blood (2018) 132 (Supplement 1): 5881.

https://doi.org/10.1182/blood-2018-99-113154

Published: 2018

Journal Articles

Burden of Morbidities Associated with Splenomegaly and From Existing Treatments In Patients with Myelofibrosis

Claire N. Harrison, DM, Benjamin R. Elkins, MPH, Kimberly Yee, MPH, Dave Nellesen, PhD, Sonia Pulgar, MPH

Blood (2010) 116 (21): 5059.

https://doi.org/10.1182/blood.V116.21.5059.5059

Published: 2010

NARROW

Tazemetostat Is Associated with Lower Risk for Safety Outcomes Versus the PI3-Kinases Idelalisib, Duvelisib and Copanlisib, in Patients with Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 2 Prior Systemic Treatments: A Matching-Adjusted Indirect Comparison of Single-Arm Trials

A Systematic Literature Review of the Burden of Central Nervous System Complications for Patients with Sickle Cell Disease

A Systematic Literature Review of the Burden of Ischemic Priapism in Patients with Sickle Cell Disease

A Systematic Literature Review to Assess Long-Term Outcomes Associated with Splenectomy in Patients with Chronic Immune Thrombocytopenia

Burden of Morbidities Associated with Splenomegaly and From Existing Treatments In Patients with Myelofibrosis

Email alerts

ASH Publications

American Society of Hematology

Tazemetostat Is Associated with Lower Risk for Safety Outcomes Versus the PI3-Kinases Idelalisib, Duvelisib and Copanlisib, in Patients with Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 2 Prior Systemic Treatments: A Matching-Adjusted Indirect Comparison of Single-Arm Trials

A Systematic Literature Review of the Burden of Central Nervous System Complications for Patients with Sickle Cell Disease

A Systematic Literature Review of the Burden of Ischemic Priapism in Patients with Sickle Cell Disease

A Systematic Literature Review to Assess Long-Term Outcomes Associated with Splenectomy in Patients with Chronic Immune Thrombocytopenia

Burden of Morbidities Associated with Splenomegaly and From Existing Treatments In Patients with Myelofibrosis

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only